Biotechs fill vacuum of drugs for treating PAH

01/18/2006 | Forbes

Biotech firms have stepped in over the past five years and filled a gap left by pharmaceutical companies by developing drugs to treat pulmonary arterial hypertension, an ailment that affects only about 200,000 people around the world.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN